Market Place
Sourcing Support
XOMA Royalty Declares Quarterly Preferred Stock Dividends
18 Mar 2026 //
GLOBENEWSWIRE
XOMA Royalty Reveals 2025 Financials And Business Milestones
18 Mar 2026 //
GLOBENEWSWIRE
XOMA Royalty Announces CFO Transition
12 Jan 2026 //
GLOBENEWSWIRE
XOMA Royalty, Takeda Strike Mezagitamab Royalty Deal
30 Dec 2025 //
GLOBENEWSWIRE
XOMA Royalty Reveals 2025 Q3 Financials & Business Milestones
12 Nov 2025 //
GLOBENEWSWIRE
Xoma And Lava Buyout Cools With Lower Offer
17 Oct 2025 //
FIERCE BIOTECH
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics
02 Oct 2025 //
GLOBENEWSWIRE
LAVA Therapeutics Moves EGM to Early November 2025
30 Sep 2025 //
GLOBENEWSWIRE
HilleVax Enter into a Definitive Agreement to be Acquired by XOMA
05 Aug 2025 //
GLOBENEWSWIRE
XenoTherapeutics to Acquire ESSA Pharma in All-Cash Deal
14 Jul 2025 //
PR NEWSWIRE
XOMA Royalty Declares Quarterly Preferred Stock Dividends
18 Jun 2025 //
GLOBENEWSWIRE
XOMA Royalty Declares Quarterly Preferred Stock Dividends
20 Mar 2025 //
GLOBENEWSWIRE
XOMA Royalty Declares Quarterly Preferred Stock Dividends
19 Dec 2024 //
GLOBENEWSWIRE
XOMA Royalty Expands Portfolio With 60 Programs From Twist
22 Oct 2024 //
GLOBENEWSWIRE
XOMA Royalty Declares Quarterly Preferred Stock Dividends
23 Sep 2024 //
GLOBENEWSWIRE
XOMA To Present At H.C. Wainwright BioConnect NASDAQ Conference
14 May 2024 //
GLOBENEWSWIRE
XOMA Q1 2024 Financials And Recent Activities
09 May 2024 //
GLOBENEWSWIRE
Daré`s royalty deal; Qlaris Bio raises $24M
30 Apr 2024 //
ENDPTS
XOMA Enters into Agreement to Acquire Kinnate Biopharma
16 Feb 2024 //
GLOBENEWSWIRE
XOMA Expands its Royalty and Milestone Portfolio with DSUVIA® Acquisition
18 Jan 2024 //
GLOBENEWSWIRE
XOMA Announces Stock Repurchase Program of up to $50 Million
02 Jan 2024 //
GLOBENEWSWIRE
XOMA Declares Quarterly Preferred Stock Dividends
25 Sep 2023 //
GLOBENEWSWIRE
XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference
06 Sep 2023 //
GLOBENEWSWIRE
XOMA Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
XOMA Added to the Russell 2000® and Russell 3000® Indexes
23 Jun 2023 //
GLOBENEWSWIRE
XOMA acquires royalty and milestone rights for NPC and pancreatic cancer assets
23 Jun 2023 //
PHARMAFILE
XOMA Reports1Q 2023 FYR and Provides Update on the Acceleration
09 May 2023 //
GLOBENEWSWIRE
XOMA to Present at H.C. Wainwright BioConnect Investor Conference
26 Apr 2023 //
GLOBENEWSWIRE
XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone Portfolio
30 Mar 2023 //
GLOBENEWSWIRE
XOMA Declares Quarterly Preferred Stock Dividends
21 Mar 2023 //
GLOBENEWSWIRE
XOMA Reports Full-Year 2022 Financial Results
09 Mar 2023 //
GLOBENEWSWIRE
XOMA to Present at 43rd Annual Cowen Health Care Conference
28 Feb 2023 //
GLOBENEWSWIRE
XOMA Acquires Royalty and Milestone License to Ebopiprant
22 Nov 2022 //
GLOBENEWSWIRE
XOMA Reports 3Q FYR and Highlights Recent Operational Events
03 Nov 2022 //
GLOBENEWSWIRE
XOMA to Present at H.C. Wainwright 24th Annual Global Investment Conference
07 Sep 2022 //
GLOBENEWSWIRE
XOMA Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
GLOBENEWSWIRE
XOMA Declares Quarterly Preferred Stock Dividend
20 Jun 2022 //
PRESS RELEASE
XOMA Reports First Quarter 2022 Financial Results
05 May 2022 //
GLOBENEWSWIRE
XOMA Declares Quarterly Preferred Stock Dividends
21 Mar 2022 //
GLOBENEWSWIRE
XOMA to Present at Oppenheimer`s 32nd Annual Healthcare Conference
10 Mar 2022 //
GLOBENEWSWIRE
XOMA Reports FY 2021 Financial Results and Highlights Recent Operational Events
08 Mar 2022 //
GLOBENEWSWIRE
XOMA to Present at the 42nd Annual Cowen Health Care Conference
01 Mar 2022 //
GLOBENEWSWIRE
XOMA to Present at Upcoming Investor Conferences
21 Dec 2021 //
GLOBENEWSWIRE
XOMA Earns $35M Milestone Payment as Anti-TGF? Ab Enters Phase 3 Clinical Study
04 Nov 2021 //
GLOBENEWSWIRE
XOMA to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conf
22 Sep 2021 //
GLOBENEWSWIRE
XOMA Announces Heather L. Franklin Joins its Board of Directors
10 Aug 2021 //
GLOBENEWSWIRE
XOMA Reports Second Quarter 2021 Financial Results
05 Aug 2021 //
GLOBENEWSWIRE
U.S. FDA Granted Orphan Drug Designation XOMA’s anti-TGFβ Asset NIS793
28 Jul 2021 //
GLOBENEWSWIRE
XOMA Acquires Royalty and Milestone Interest in Checkmate’s Vidutolimod
15 Jul 2021 //
GLOBE NEWSWIRE
XOMA Declares Quarterly Preferred Stock Dividends
21 Jun 2021 //
GLOBENEWSWIRE
XOMA Prices $35 Million Offering of Depositary Shares
06 Apr 2021 //
GLOBENEWSWIRE
XOMA Announces Offering of Depositary Shares and Series B Cumulative
05 Apr 2021 //
BIOSPACE
Viracta and XOMA Announce Multi-License Milestone and Royalty
23 Mar 2021 //
PRNEWSWIRE
Viracta and XOMA Announce Multi-License Milestone and Royalty Monetization
23 Mar 2021 //
BIOSPACE
XOMA Announces Exercise of Green Shoe Option and Closes Preferred Stock Offering
21 Dec 2020 //
GLOBENEWSWIRE
XOMA Prices $22 Million Offering of Series A Cumulative Perpetual
10 Dec 2020 //
GLOBENEWSWIRE
XOMA Earns $2M Takeda Milestone
17 Nov 2020 //
CONTRACTPHARMA
XOMA Highlights Recent Royalty Asset Portfolio Developments and Reports
05 Nov 2020 //
GLOBENEWSWIRE
XOMA Acquires Royalty Interest Four Lysosomal Storage Disorder Enzymes Developed
03 Nov 2020 //
BIOSPACE
